RxDoctor Payments Data

Vidang Nguyen, MD

Advanced Heart Failure and Transplant Cardiology · Portland, ORNPI 1154663987

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abiomed accounts for 81.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $19,661 and has fallen 87.8% since, to $2,397 in 2025.

$27,441in general payments, 2019–2025

Across 119 payments — averaging $230.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$22K
  • Ancora Heart, Inc.$2K
  • Abbott$809
  • Medtronic$770
  • AstraZeneca$709
  • Boehringer Ingelheim$246
  • plus $648 from 6 others
$46,424in research payments, 2019–2025

Across 1 payment — averaging $46,424 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endotronix, Inc.$46K

What the payments were for

  • Speaking & faculty fees$16,20059%
  • Travel & lodging$3,30312%
  • Food & beverage$7,83829%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abiomed67$22,386
Ancora Heart, Inc.12$1,873
Abbott12$809
Medtronic(2 entities)4$770
AstraZeneca11$709
Boehringer Ingelheim2$246
Cvrx, Inc.3$238
Paragonix Technologies, Inc.3$160
Impulse Dynamics (USA) Inc.1$125
Cardiac Dimensions, Inc.2$69
Nuwellis, Inc.1$33
Bridgebio Pharma, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Oregonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$58,997
Medicare patients
192
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan381$500,745
FarxigaDapagliflozin Propanediol241$259,230
JardianceEmpagliflozin160$204,223
EliquisApixaban178$200,349
XareltoRivaroxaban17$20,137
DapagliflozinDapagliflozin Propanediol22$18,330
Metoprolol Succinate371$5,064
Torsemide167$4,615
Spironolactone354$3,226
Atorvastatin Calcium222$3,154
Cyclosporine ModifiedCyclosporine, Modified26$2,754
Potassium Chloride94$2,661
Eplerenone25$2,214
Tacrolimus41$2,198
Bumetanide25$1,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$709$259,230241 claims
Boehringer IngelheimJardiance$246$204,223160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Oregonon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →